In 2022, EUHASS collected data on 9614 patients with nonsevere hemophilia A and 2274 patients with nonsevere hemophilia B. Overall, the centers reported 36,074 treatment years for nonsevere hemophilia A and 9238 treatment years for nonsevere hemophilia B. Treatment years (n = 259) on emicizumab (Hemlibra) were excluded from analysis, as well as 73 treatment years (without inhibitors) on unlicensed clinical products, which included both FVIII and FIX concentrates. The gene discussed is F8; the disease is hemophilia B.